An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...

and PTSD with cutting-edge treatments like the dual sympathetic reset (an advanced stellate ganglion block (SGB), Spravato, ketamine infusion therapy, TMS therapy and more. It starts with an ...

If you’ve found traditional treatments insufficient and are ready to explore innovative therapies like IV ketamine infusions, TMS, or Spravato, you are in the right place. We’re dedicated to ...

Kadima offers ketamine therapy, the prescription nasal spray medication Spravato and transcranial magnetic stimulation – a non-invasive treatment that uses magnetic pulses to stimulate specific ...